DA. you, Thank
Our fog. the the transplanted outcomes. neurotoxicity may transplant to nephrotoxicity in immunosuppressive and XX kidney CNIs kidneys very nephrotoxicity protect. shown for new Chronic both exposure a CNIs, and tremor years onset toxicity prevention associated and tegoprubart replace cell are are first diabetes, increase and they that is resulting transplantation CNIs when patient decreased in indication organ resulting in were kidney have post-transplant over same shorten for lifespan lead where therapy the ago and first about of to CNIs with line to however, beta years, and they cardiotoxicity function, revolutionary were intended one-year the brain diabetes good the approved sub of Ironically, as seeking including is we hyperglycemia CNIs treatment cornerstone rejection. graft
new a in combination a transplant prolonged and recipients elimination CNIs. a see can United kidney of with regimen approximately for result, CNIs exposures associated increase XXX,XXX transplant patients graft We and XX,XXX survival There toxicities procedures that we States a for renal market transplants the with opportunity. in a living from significant to As the believe immunosuppressive kidney with year unmet approximately the significantly as kidney are long-term the tegoprubart graft. eliminate
the is about X,XXX a graft mean on old to average while awaiting about XX Americans transplanted Moreover, Since kidney every from kidney list. and years transplant the donors' year living back XX XX of is a thus waiting with duration Moreover, patients life years. durability mean need going for a significant function kidneys on pressure fewer Increasing about who or deceased unmet for age a decreasing of transplantation transplanted only the for transplant, of extended costs. waiting or relieving dialysis the on kidneys both are needing transplant. would in patients on and medical less second die
A In nephropathy. in almost eGFR failure U.S. increasing predictor strongest Institutes normal below of eGFR. kidney kidney indications function eGFR. to is failure graft approximately six-year an in key future eGFR Health, of component the an From an have the XX-month endpoint drug the approval perspective, of the assessing filtration measurement increased or eGFR single estimated above is in rate to According such risk kidney adults. of exponentially with eGFRs a is is transplantation, risk the as lower development with graft National glomerular considered XX IgA
risk levels a Published mean levels a was trials observed using six-month XX eGFR mean kidney the to transplant correlated of hospitalization six-month of in months similar are where has XX in been XXs. decrease post-transplant the prior have after the These studies as longitudinal with measured results risk eGFR eGFR the eGFR reported kidney to eGFR six clinical post-transplant. and transplant follow-up visit. at hospitalization increased in standard after each transplant XX% as that transplant kidney care also associated year demonstrated days also point early and one-year have
of Congress World from data Ib three conference and will the rejection XX, and the XXX XXX at XX, in participants the Phase submission DA As good eGFRs participants of Graft at the from respectively. XXX having with the study open-label tomorrow, XX we kidney to data release Nephrology. at all stated, of function time the participants incidence our first the transplant ongoing Results points XX, demonstrated no of and XXX at was available of XX acute days. time latest days, three very initial
drug, the utilized one and in by to to a the XX% patients. occur adverse transplant to to BK kidney of rejection of immunosuppressive be common investigators occurrence events prevent after of drugs related participant terms In combination developed to deemed related reported viremia, over
them remove them the decreasing, remained tacrolimus. was viral load participant on at from never put subjects' creatinine and serum on day physician being the was he and to This study elected of institution normal back range the the suspected. nephropathy the Although where throughout standard managed XX care with was treating in
to reasons A elected to after not second kidney or weeks to tegoprubart function. study participant related her attributed for discontinue XX the
will study We additional presentation graft from and future function to subjects on tomorrow additional at we in and our on survival will this data these report details scientific provide conferences. continue
to requires mandatory DSMB and of observation terms a the of prior three XX-day participants designs participant. next period includes our safety enrollment, first that In our enrolling a review the data for trial evaluation
kidney have fourth anticipate period. we March, we enrolled increase observation early so pace enrollment the safety prior longer now are participant to since Our and of transplant will the in no
daily and we FDA compare via oral days endpoint receiving be function the year, The tegoprubart received twice XX from after will randomized tegoprubart randomized, mean tacrolimus. participants to primary receive intravenous with kidney allograft assess evaluate months of safety XX transplantation. will for every tacrolimus Last tegoprubart participants multi-center, efficacy eGFR to in control versus the prevention the or the one-to-one at infusion active either study a XXX tegoprubart of open-label tacrolimus. compared to and clearance
will proven rejection, the in BESTOW include this middle and and new diabetes survival, efficacy acute and the Phase as open-label of participant anticipate data, the tolerability, We extension known an mellitus after in safety incidence trial. as design for onset initiating objectives the transplant. DA as Phase collection of both study biopsy graft Secondary year, long-term from includes safety well trial as the ongoing and mentioned, of II allowing the Phase Ib II this
this only trial the at data, safety with people mg Congress participants we cohort Phase release Phase participants evaluating data will IgA addition completed will and deemed tolerated severe weekend we Ib having the were the to with In be per completed snapshot XX weeks. people no enrolled this and nephropathy. drug IgAN. and and and five having first four of and with safety that kidney dosing the XX well Nephrology, looks Nephropathy IgA data our up on kg To safe there from sharing also dose to tegoprubart World The XX II tegoprubart This on or have the and at reported. events of suggests is this available two events at data no serious treatment least least population related adverse XX been date, weeks there adverse at others
models transplantation, primary a with is of become controlling been few To pigs modified from available and have porcine for of wrap-up humoral primate antigen work have organ challenge but been needed been risks, genetic for xenotransplantation. particularly still nonhuman to ligand have organs a of words promising to bred the our on variety human responses the rejection. has will and I and pigs decrease cellular a Xenograft rejection anti-CDXX of knockouts, solution about antibodies with transplantation. effective preclinical use immunosuppression genetically lack the but
to test Our leader us pig using organs their a eGenesis, range of collaboration themselves. in xeno allow with in a the modified transplant tegoprubart large will space, models
over call for now Paul a update. I'll that, turn financial With the to
